Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting.
White J, Shenoy BV, Tutrone RF, Karsh LI, Saltzstein DR, Harmon WJ, Broyles DL, Roddy TE, Lofaro LR, Paoli CJ, Denham D, Reynolds MA. White J, et al. Among authors: saltzstein dr. Prostate Cancer Prostatic Dis. 2018 Apr;21(1):78-84. doi: 10.1038/s41391-017-0008-7. Epub 2017 Nov 20. Prostate Cancer Prostatic Dis. 2018. PMID: 29158509 Free PMC article.
A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM. Parekh DJ, et al. Among authors: saltzstein dr. Eur Urol. 2015 Sep;68(3):464-70. doi: 10.1016/j.eururo.2014.10.021. Epub 2014 Oct 27. Eur Urol. 2015. PMID: 25454615
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, Bailen JL, Shi H, Ye Z, Faessel HM, Lin H, Zhu Y, Saad F, MacLean DB, Shore ND. Dearnaley DP, et al. Among authors: saltzstein dr. Eur Urol. 2020 Aug;78(2):184-192. doi: 10.1016/j.eururo.2020.03.001. Epub 2020 Apr 6. Eur Urol. 2020. PMID: 32273183 Free article. Clinical Trial.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. Among authors: saltzstein dr. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.
Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, Steiner MS, Saltzstein DR, Eisenberger MA, Antonarakis ES. Markowski MC, et al. Among authors: saltzstein dr. Clin Cancer Res. 2022 Jul 1;28(13):2789-2795. doi: 10.1158/1078-0432.CCR-22-0162. Clin Cancer Res. 2022. PMID: 35416959 Free PMC article. Clinical Trial.
Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
George DJ, Saad F, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Buckley D, Tombal B, Shore ND. George DJ, et al. Among authors: saltzstein dr. Clin Genitourin Cancer. 2023 Jun;21(3):383-392.e2. doi: 10.1016/j.clgc.2023.03.009. Epub 2023 Mar 24. Clin Genitourin Cancer. 2023. PMID: 37062659 Free article. Clinical Trial.
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Shore ND, Mehlhaff BA, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Fallick M, Hanson S, Saad F. Shore ND, et al. Among authors: saltzstein dr. Adv Ther. 2023 Nov;40(11):4919-4927. doi: 10.1007/s12325-023-02634-7. Epub 2023 Sep 15. Adv Ther. 2023. PMID: 37713020 Free PMC article. Clinical Trial.
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tutrone R, Saad F, George DJ, Tombal B, Bailen JL, Cookson MS, Saltzstein DR, Hanson S, Brown B, Lu S, Fallick M, Shore ND. Tutrone R, et al. Among authors: saltzstein dr. Eur Urol Oncol. 2023 Dec 23:S2588-9311(23)00290-0. doi: 10.1016/j.euo.2023.11.024. Online ahead of print. Eur Urol Oncol. 2023. PMID: 38143206 Free article.
29 results